Introduction: The ICH-GCP (International Council for Harmonisation — Good Clinical Practice) guideline is a cornerstone of clinical research, blending ethical considerations with scientific standards to ensure the safety, rights, and well‑being of trial participants while assuring reliable, credible data. This blog presents focused MCQs on the origin, evolution, scope, and core principles of ICH-GCP tailored for M.Pharm students. Questions probe regulatory history, roles of sponsor/investigator/ethics committees, informed consent, documentation, safety reporting, monitoring, and recent E6 revisions. Practicing these MCQs reinforces conceptual clarity and prepares students for regulatory and clinical research responsibilities in diverse global settings.
Q1. Which statement best describes the primary origin and purpose of the ICH?
- To create a single global agency that approves drugs for all member countries
- To harmonize technical requirements for the registration of pharmaceuticals for human use among EU, US and Japan
- To replace national regulations with a uniform law enforced by the ICH secretariat
- To provide funding for multinational clinical trials
Correct Answer: To harmonize technical requirements for the registration of pharmaceuticals for human use among EU, US and Japan
Q2. What does GCP stand for in the context of ICH guidelines?
- Global Clinical Procedures
- Good Clinical Practice
- General Clinical Protocol
- Guidance for Clinical Pharmacology
Correct Answer: Good Clinical Practice
Q3. Which ICH guideline number specifically addresses Good Clinical Practice?
- ICH E6
- ICH Q1A
- ICH M4
- ICH S7
Correct Answer: ICH E6
Q4. What is the primary objective of ICH-GCP?
- To speed up clinical trials by reducing documentation requirements
- To ensure publication of all clinical data in peer‑reviewed journals
- To protect the rights, safety and well‑being of trial subjects and ensure credibility of clinical data
- To standardize drug pricing across ICH regions
Correct Answer: To protect the rights, safety and well‑being of trial subjects and ensure credibility of clinical data
Q5. Who is primarily responsible for initiating, managing and financing a clinical trial?
- Investigator
- Sponsor
- Ethics Committee
- Contract Research Organization (CRO)
Correct Answer: Sponsor
Q6. Which of the following is a core responsibility of the Investigator under ICH-GCP?
- Preparing regulatory marketing submissions to authorities
- Ensuring subjects give voluntary informed consent and conducting the trial according to the protocol
- Approving multicenter trial budgets
- Issuing final regulatory approvals for the investigational product
Correct Answer: Ensuring subjects give voluntary informed consent and conducting the trial according to the protocol
Q7. According to ICH-GCP, for how long should essential clinical trial documents generally be retained?
- At least 6 months after the last study visit
- Indefinitely without exception
- At least 2 years after the last approval of a marketing application in an ICH region or as required by applicable regulatory requirements
- Until the investigator retires
Correct Answer: At least 2 years after the last approval of a marketing application in an ICH region or as required by applicable regulatory requirements
Q8. What is an Independent Ethics Committee (IEC) primarily responsible for?
- Designing the clinical protocol
- Monitoring the study budget and timelines
- Protecting the rights, safety and well‑being of trial participants through protocol and consent review
- Manufacturing the investigational product
Correct Answer: Protecting the rights, safety and well‑being of trial participants through protocol and consent review
Q9. When must informed consent be obtained according to ICH-GCP?
- Any time before database lock
- Only after the first dose is given
- Prior to undertaking any trial‑related procedures or participation in the trial
- After adverse events have been explained to the subject
Correct Answer: Prior to undertaking any trial‑related procedures or participation in the trial
Q10. An investigator experiences a serious adverse event (SAE) in a trial participant. Within what timeframe should the investigator notify the sponsor?
- Within 24 hours
- Within 30 days
- Within 6 months
- No requirement to notify the sponsor
Correct Answer: Within 24 hours
Q11. Which activity best describes the role of a clinical monitor (CRA) under ICH-GCP?
- Performing statistical analysis of trial data
- Ensuring the trial is conducted, recorded and reported in accordance with the protocol, SOPs, GCP and applicable regulatory requirements through site visits and source data verification
- Issuing regulatory approvals on behalf of the sponsor
- Prescribing medication to trial subjects
Correct Answer: Ensuring the trial is conducted, recorded and reported in accordance with the protocol, SOPs, GCP and applicable regulatory requirements through site visits and source data verification
Q12. What is the main purpose of randomization in clinical trials?
- To blind participants to treatment
- To ensure equal numbers of male and female participants
- To reduce selection bias and help balance known and unknown prognostic factors between treatment groups
- To speed up recruitment
Correct Answer: To reduce selection bias and help balance known and unknown prognostic factors between treatment groups
Q13. Which statement best defines allocation concealment?
- Hiding the treatment identity from outcome assessors only
- Preventing foreknowledge of treatment assignment to those enrolling participants to avoid selection bias
- Ensuring the randomization list is published publicly
- Concealing the investigator’s name from the sponsor
Correct Answer: Preventing foreknowledge of treatment assignment to those enrolling participants to avoid selection bias
Q14. Blinding (masking) an investigator in a trial is primarily intended to:
- Increase sample size
- Reduce bias in assessing outcomes and managing subjects
- Reduce documentation requirements
- Shorten trial duration
Correct Answer: Reduce bias in assessing outcomes and managing subjects
Q15. Under ICH-GCP, the definition of an adverse event (AE) includes which of the following?
- Only events definitely caused by the investigational product
- Any untoward medical occurrence in a subject temporally associated with the use of an investigational product, whether or not related
- Only events leading to hospitalization
- Only expected effects listed in the investigator brochure
Correct Answer: Any untoward medical occurrence in a subject temporally associated with the use of an investigational product, whether or not related
Q16. Which countries were the founding regulatory regions participating in the original ICH harmonization effort?
- China, India and Brazil
- European Union, Japan and the United States
- Australia, Canada and South Africa
- Russia, Mexico and South Korea
Correct Answer: European Union, Japan and the United States
Q17. Who is responsible for preparing the Investigator’s Brochure (IB)?
- The Investigator at the clinical site
- The Sponsor
- The Ethics Committee
- The Regulatory Authority
Correct Answer: The Sponsor
Q18. Which elements are essential components of a clinical trial protocol according to ICH-GCP?
- Only the investigational product name and the investigator’s CV
- Objectives, design, methodology, statistical considerations and organization of the trial
- Marketing strategy and pricing details
- Only the informed consent form and the budget
Correct Answer: Objectives, design, methodology, statistical considerations and organization of the trial
Q19. ICH-GCP applies to which types of studies?
- Non‑clinical animal studies only
- Clinical trials involving human subjects conducted for regulatory submissions
- Basic laboratory assays unrelated to human trials
- Only post‑marketing observational studies
Correct Answer: Clinical trials involving human subjects conducted for regulatory submissions
Q20. The ICH E6(R2) addendum emphasized which modern approaches to improve trial quality?
- Eliminating monitoring and relying entirely on paper records
- Risk‑based quality management, risk‑based monitoring and enhanced oversight of trial processes
- Mandatory single‑center trials only
- Removal of responsibility from sponsors to ensure trial quality
Correct Answer: Risk‑based quality management, risk‑based monitoring and enhanced oversight of trial processes
